the esports solutions provider has announced it will host the third open event of the 2019 Call of Duty® World League season, at the 7,500 capacity Copper Box Arena in London running 3rd-5th May 2019.
Garry Cook, Executive Chairman of Gfinity, said: "In May, London will become the focus of the gaming world. Gfinity is going to put on a show and deliver an experience that will excite the global Call of Duty® esports community.”
The event, presented by PlayStation®4, will feature 16 of the top Call of Duty World League professional teams who will compete for prizes. There will also be an amateur tournament with up to 200 teams participating, with its own dedicated prize pool.
Mr. Garry Cook said “We know the players and fans and the passion they will bring to the Copper Box Arena. London is in for a treat."
The company said it won the contract after a competitive tender due to its strong track record in the managed esports business and end-to-end esports solutions. It expects the agreement to offer additional revenue opportunities through ticket sales and commercial rights.
The 2019 Call of Duty World League season launched in December 2018 in Las Vegas and recorded the highest views for an opening weekend in CWL history.
It also saw the largest number of teams, the largest number of competitors and a 100% increase in social engagement from last year's season opener, according to Activision internal data.
Follow News & Updates from Gfinity here:
Peter Webb, fund manager turned market commentator looks at PCF Group.
SP Angel morning look at commodities and miners, featuring: Anglo Asian Mining (AAZ LN) BUY – 96p (from 108p) – Earnings update Glencore (GLEN LN) – Glencore claim record EBITDA on strong copper mine performance Landore Resources (LND LN) – BAM Gold Preliminary Economic Assessment Pan African Resources (PAF LN) – Earnings climb as operations refocus on profitable ounces Transense Technologies plc (TRT LN) – 2nd mining contract announced this week for mining heavy truck tracking & tyre pressure monitoring
In a conference call to investors and analysts, Motif Bio confirmed that the FDA had no questions over the clinical efficacy of Iclaprim. However the FDA stated it needs additional data to further evaluate the risk for liver toxicity before the NDA approval.
Five financial stories, trending today in a 70 second podcast, including: The number of people in work in the UK has continued to climb, with a record 32.6 million employed between October and December The jobless rate, remaining at 4%, is at its lowest since early 1975.